<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:department>Sch of Chemistry</gtr:department><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/D7F1E893-E407-4BD7-B91C-EB96070706AA"><gtr:id>D7F1E893-E407-4BD7-B91C-EB96070706AA</gtr:id><gtr:firstName>Susan</gtr:firstName><gtr:surname>Watson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/FC2273EF-F4F4-4B2E-9DFE-D515644698CE"><gtr:id>FC2273EF-F4F4-4B2E-9DFE-D515644698CE</gtr:id><gtr:firstName>Amalia</gtr:firstName><gtr:surname>Patane</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/0EA34071-A9BA-439D-87E9-281C050081F6"><gtr:id>0EA34071-A9BA-439D-87E9-281C050081F6</gtr:id><gtr:firstName>Anna Maria</gtr:firstName><gtr:surname>Grabowska</gtr:surname><gtr:orcidId>0000-0003-1507-921X</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/AFDB8535-9143-4FF4-943B-D65A98AB7CBD"><gtr:id>AFDB8535-9143-4FF4-943B-D65A98AB7CBD</gtr:id><gtr:firstName>Neil</gtr:firstName><gtr:otherNames>R</gtr:otherNames><gtr:surname>Thomas</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0801741"><gtr:id>87C33C21-1848-497A-A051-09DBAA689048</gtr:id><gtr:title>Harnessing Self assembly to generate a spectrum of multi-functionalised nanoparticles for multimodal imaging</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0801741</gtr:grantReference><gtr:abstractText>We will use a protein that can self assemble from its subunits into a capsule as a vehicle for imaging inside patients using magnetic resonance or tomography and in the longer term delivering drugs to specific tissues such as tumours. As the individual building blocks of the protein capsule can be modified in different ways, the capsule can be optimised on an individual basis based on patient need.</gtr:abstractText><gtr:technicalSummary>Ferritin subunits containing un-natural azido bearing amino acids will be produced and MRI, fluorescence and PET probes added using click chemistry. The subunits will then be mixed in known ratios and apoferritin protein capsules will self assemble. These nanoparticles will be characterised by DLS, TEM, fluorescence and MRI/PET before being evaluated for their localisation and imaging properties in mice.</gtr:technicalSummary><gtr:fund><gtr:end>2012-11-10</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-05-11</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>516644</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Nottingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Biosciences Nottingham</gtr:department><gtr:description>UoN - Ultracentrifugation studies</gtr:description><gtr:id>099E6E6F-7CDA-442B-BE99-E6DCB5EBCED1</gtr:id><gtr:impact>Paper in prearation</gtr:impact><gtr:partnerContribution>Characterisation of materials we have produced by utracentrifugation</gtr:partnerContribution><gtr:piContribution>Apoferritin-QD and engineered apoferritins studied for their self assembly properties by analytical ultracentrifugation (AUC) studies</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Bristol</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Chemistry Bristol</gtr:department><gtr:description>Univ. Bristol TEM studies</gtr:description><gtr:id>105B7E5F-19BF-4CBF-ADFA-F8A861FF9E0E</gtr:id><gtr:impact>Publication on toxicity of composites under preparation</gtr:impact><gtr:partnerContribution>Characterisation of hybrd materials we have made by TEM.</gtr:partnerContribution><gtr:piContribution>Provided the Apoferritin (human and mouse) PbS quantum dots for TEM studies at Bristol</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Nottingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Biological evaluation of Quantum Dots-apofferitin composites</gtr:description><gtr:id>E4AA62B0-4295-44CE-B75C-0EF20DD9C86C</gtr:id><gtr:impact>TURYANSKA, L., BRADSHAW, T. D., SHARPE, J., LI, M., MANN, S., THOMAS, N. R. and PATANE, A., 2009. The Biocompatibility of Apoferritin-Encapsulated PbS Quantum Dots. Small, 5(15), 1738-1741.</gtr:impact><gtr:partnerContribution>Testing the toxicity of our apoferritin/Quantum dot composits against a panel of cell lines.</gtr:partnerContribution><gtr:piContribution>Preparation of the apoferritin/quantum dots</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Bristol</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Chemistry Bristol</gtr:department><gtr:description>Characterisation of apoferritin QDs by TEM</gtr:description><gtr:id>B2CCAA74-4970-4A23-8D8D-6681C2D0D47A</gtr:id><gtr:impact>19360723 and HENNEQUIN, B., TURYANSKA, L., BEN, T., BELTRAN, A. M., MOLINA, S. I., LI, M., MANN, S., PATANE, A. and THOMAS, N. R., 2008. Aqueous Near-Infrared Fluorescent Composites Based on Apoferritin-Encapsulated PbS Quantum Dots. Advanced Materials, 20(19), 3592-3596</gtr:impact><gtr:partnerContribution>TEM studies on our apoferritin/quantum dot strutures</gtr:partnerContribution><gtr:piContribution>Preparation of apoferritin-QDs</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>70000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Anne McLaren Fellowship (for L. Turyanska)</gtr:description><gtr:end>2010-12-02</gtr:end><gtr:fundingOrg>University of Nottingham</gtr:fundingOrg><gtr:id>78852092-1E6A-478E-9123-F5F338B6029B</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>human and mouse apoferritin light subunits with azidohomoaanine at specific positions have been produced. These will allow specific attacment of fluorophores or other ligands on to the azido group using click chemistry.</gtr:description><gtr:id>F15C8702-0B30-4FCB-8348-06E475EA97C4</gtr:id><gtr:impact>Too early to say</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>human and mouse apoferritin with un-natural amino acids</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D8371759-861F-43CA-B1B6-39B09C7FF17B"><gtr:id>D8371759-861F-43CA-B1B6-39B09C7FF17B</gtr:id><gtr:title>The differential effect of apoferritin-PbS nanocomposites on cell cycle progression in normal and cancerous cells</gtr:title><gtr:parentPublicationTitle>J. Mater. Chem.</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/81c37159cdfca3015b43ee2fbe8b1899"><gtr:id>81c37159cdfca3015b43ee2fbe8b1899</gtr:id><gtr:otherNames>Turyanska L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5768D88D-82CF-40C1-977C-653CC3C9F209"><gtr:id>5768D88D-82CF-40C1-977C-653CC3C9F209</gtr:id><gtr:title>A concise and scalable route to L-azidohomoalanine.</gtr:title><gtr:parentPublicationTitle>Nature protocols</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/94d79bacc4a7f1010c079d1e64a0a766"><gtr:id>94d79bacc4a7f1010c079d1e64a0a766</gtr:id><gtr:otherNames>Roth S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1750-2799</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5F02BECD-19FB-42D1-8F83-FC2EB6F6AA25"><gtr:id>5F02BECD-19FB-42D1-8F83-FC2EB6F6AA25</gtr:id><gtr:title>Apoferritin-encapsulated PbS quantum dots significantly inhibit growth of colorectal carcinoma cells</gtr:title><gtr:parentPublicationTitle>Journal of Materials Chemistry B</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6abe3c468e83cc8812809b81ad307e6a"><gtr:id>6abe3c468e83cc8812809b81ad307e6a</gtr:id><gtr:otherNames>Bradshaw T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A6B7CE60-FDDC-4E3F-9DDE-1E6899432791"><gtr:id>A6B7CE60-FDDC-4E3F-9DDE-1E6899432791</gtr:id><gtr:title>Developing Mn-doped lead sulfide quantum dots for MRI labels</gtr:title><gtr:parentPublicationTitle>J. Mater. Chem. B</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/81c37159cdfca3015b43ee2fbe8b1899"><gtr:id>81c37159cdfca3015b43ee2fbe8b1899</gtr:id><gtr:otherNames>Turyanska L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/92975830-3E40-4568-9354-9F77A0603C0D"><gtr:id>92975830-3E40-4568-9354-9F77A0603C0D</gtr:id><gtr:title>Ligand-Induced Control of Photoconductive Gain and Doping in a Hybrid Graphene-Quantum Dot Transistor</gtr:title><gtr:parentPublicationTitle>Advanced Electronic Materials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/81c37159cdfca3015b43ee2fbe8b1899"><gtr:id>81c37159cdfca3015b43ee2fbe8b1899</gtr:id><gtr:otherNames>Turyanska L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2BA8B79C-DF0E-4853-BA75-4AF429600987"><gtr:id>2BA8B79C-DF0E-4853-BA75-4AF429600987</gtr:id><gtr:title>An Apoferritin-based Drug Delivery System for the Tyrosine Kinase Inhibitor Gefitinib.</gtr:title><gtr:parentPublicationTitle>Advanced healthcare materials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0729510f4cdd5f646337e54db3a3700a"><gtr:id>0729510f4cdd5f646337e54db3a3700a</gtr:id><gtr:otherNames>Kuruppu AI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2192-2640</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BAC7CAA0-30CD-44DF-BCF3-347EC333F35E"><gtr:id>BAC7CAA0-30CD-44DF-BCF3-347EC333F35E</gtr:id><gtr:title>Fabrication of polypyrrole nano-arrays in lysozyme single crystals.</gtr:title><gtr:parentPublicationTitle>Nanoscale</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a2bda5bcb8954dff9dc40e5ba7b83415"><gtr:id>a2bda5bcb8954dff9dc40e5ba7b83415</gtr:id><gtr:otherNames>England MW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>2040-3364</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1C539230-7F46-4F22-A4A9-B736F18D29C8"><gtr:id>1C539230-7F46-4F22-A4A9-B736F18D29C8</gtr:id><gtr:title>Photoluminescence of PbS nanocrystals at high magnetic fields up to 30 T</gtr:title><gtr:parentPublicationTitle>Physical Review B</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/81c37159cdfca3015b43ee2fbe8b1899"><gtr:id>81c37159cdfca3015b43ee2fbe8b1899</gtr:id><gtr:otherNames>Turyanska L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8F689CF2-04A7-4C91-8F32-D5B1C925765D"><gtr:id>8F689CF2-04A7-4C91-8F32-D5B1C925765D</gtr:id><gtr:title>High magnetic field quantum transport in Au nanoparticle-cellulose films.</gtr:title><gtr:parentPublicationTitle>Nanotechnology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/81c37159cdfca3015b43ee2fbe8b1899"><gtr:id>81c37159cdfca3015b43ee2fbe8b1899</gtr:id><gtr:otherNames>Turyanska L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0957-4484</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0801741</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>